Get the Stockscreener App
17.85
1.48%
0.26
Forte Biosciences Inc stock is traded at $17.85, with a volume of 228.69K.
It is up +1.48% in the last 24 hours and down -14.88% over the past month.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
See More
Previous Close:
$17.59
Open:
$17.84
24h Volume:
228.69K
Relative Volume:
0.78
Market Cap:
$365.55M
Revenue:
-
Net Income/Loss:
$-75.86M
P/E Ratio:
-3.4953
EPS:
-5.1069
Net Cash Flow:
$-59.39M
1W Performance:
+2.59%
1M Performance:
-14.88%
6M Performance:
-37.89%
1Y Performance:
+43.43%
1-Day Range:
$17.65
$18.57
1-Week Range:
$17.00
$18.57
52-Week Range:
$9.10
$35.80
Forte Biosciences Inc Stock (FBRX) Company Profile
Name
Forte Biosciences Inc
Sector
Industry
Phone
(310) 618-6994
Address
3060 PEGASUS PARK DRIVE, DALLAS, CA
Compare FBRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBRX
Forte Biosciences Inc
|
17.85 | 365.55M | 0 | -75.86M | -59.39M | -5.1069 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-25 | Initiated | Evercore ISI | Outperform |
| Aug-18-25 | Initiated | Guggenheim | Buy |
| Jan-21-25 | Initiated | TD Cowen | Buy |
| Apr-08-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Sep-20-21 | Upgrade | Chardan Capital Markets | Sell → Buy |
| Sep-03-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Sep-03-21 | Downgrade | Chardan Capital Markets | Buy → Sell |
| Sep-03-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-03-21 | Downgrade | Truist | Buy → Hold |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Mar-26-21 | Initiated | Citigroup | Buy |
| Aug-28-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-25-20 | Initiated | Truist | Buy |
View All
Forte Biosciences Inc Stock (FBRX) Latest News
Forte Biosciences Inc (FBRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Forte Biosciences Inc (FBRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Forte Biosciences Inc (FBRX) Institutional Confidence - TradingKey
Forte Biosciences Inc (FBRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Forte Biosciences Inc (FBRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Forte Biosciences (FBRX) CFO receives 22,000 stock options grant - Stock Titan
Forte Biosciences (FBRX) awards 500,000 stock options to insider Wagner - Stock Titan
Forte Biosciences Inc (FBRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Forte Biosciences Inc (FBRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Forte Biosciences Inc (FBRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Forte Biosciences (FBRX) Dips Nearly 5%: Testing Key Support at $16.29Revenue Weighted - newsline.com
One Forte Biosciences Insider Raised Stake By 30% In Previous Year - Yahoo Finance
[EFFECT] Forte Biosciences, Inc. SEC Filing - Stock Titan
FBRX Q1 2026 Earnings: Wider-than-Expected Loss as Biotech Continues DevelopmentMargin Guidance - newsline.com
Trading Systems Reacting to (FBRX) Volatility - Stock Traders Daily
Millennium Group (FBRX) reports shared control of 1,062,182 shares - Stock Titan
Forte Biosciences (FBRX) Edges Lower Amid Sector Volatility, Key Support HoldsSmart Money Flow Stocks - newsline.com
Number of shareholders of Forte Biosciences Inc. – GETTEX:37T - TradingView
Forte Biosciences (FBRX) Slips 1% as Stock Consolidates Between Key Support and ResistanceTrend Continuation Trade - newsline.com
Forte Biosciences (NASDAQ: FBRX) files $500M shelf to sell securities - Stock Titan
Forte Biosciences Shareholders Approve Directors and Governance Items - TipRanks
Forte Biosciences (NASDAQ: FBRX) director receives 18,353 RSU equity award - Stock Titan
Forte Biosciences (NASDAQ: FBRX) files $500M shelf; highlights FB102 clinical wins - Stock Titan
Forte Biosciences (FBRX) director awarded 18,353 restricted stock units in equity grant - Stock Titan
Forte Biosciences (FBRX) director granted 18,353 RSUs in equity award - Stock Titan
Forte Biosciences (FBRX) director awarded 18,353 RSUs vesting after 2026 meeting - Stock Titan
Director at Forte Biosciences (NASDAQ: FBRX) awarded 18,353 RSUs as equity grant - Stock Titan
Forte Biosciences (FBRX) awards 18,353 RSUs to director Steven Kornfeld - Stock Titan
Forte Biosciences (FBRX) stockholders approve amended 2021 equity incentive plan - Stock Titan
FBRX Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues Clinical Progress - newsline.com
Forte Biosciences (FBRX) price target increased by 19.72% to 65.02 - MSN
Forte Biosciences Slides As Insider Purchases Lose Another US$70k - simplywall.st
Forte Biosciences Inc stock (US34960P1012): shares slip after recent Q1 loss and high volatility - AD HOC NEWS
FBRX - Finviz
FBRX Q1 2026 Earnings: Pre-Revenue Biotech Reports Narrow EPS Miss Amid Ongoing DevelopmentSurprise Factor Analysis - newsline.com
Forte Biosciences Q1 2026 Earnings: Pre-revenue Biotech Misses EPS Estimates; Stock Dips on Narrower Loss MissTech Earnings Analysis - The Legal Advocate
FBRX Q1 2026 Earnings: Wider-than-Expected Loss Reflects Pre-Revenue Biotech RealityLive Trade Sharing - Newser
Forte Biosciences stock (US34960P1012): Q1 update keeps focus on skin disease pipeline - AD HOC NEWS
(FBRX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Forte Biosciences Inc stock (US34960P1012): clinical pivot and cash focus keep biotech investors ale - AD HOC NEWS
Forte Biosciences stock (US34960P1012): volatile biotech after recent sell-off tests investor nerves - AD HOC NEWS
Forte Biosciences stock (US34960P1012): New 13G filings highlight major holders - AD HOC NEWS
Forte Biosciences Stock: Targeting Celiac Disease (NASDAQ:FBRX) - Seeking Alpha
OrbiMed entities hold 5.8% of Forte Biosciences (FBRX), ownership split disclosed - Stock Titan
Point72 entities report 0% ownership in Forte Biosciences (FBRX) - Stock Titan
MPM BioImpact LLC takes a 7.2% position in Forte Biosciences (NASDAQ: FBRX) - Stock Titan
Alger Associates (NASDAQ: FBRX) reports 1.27M shares; 10.2% stake - Stock Titan
Janus Henderson (FBRX) discloses 9.99% holding; 299,798 pre-funded warrants - Stock Titan
Forte Biosciences (NASDAQ: FBRX) deepens Q1 loss while FB102 wins Fast Track - Stock Titan
Affinity Asset Advisors takes 7.3% stake in Forte Biosciences (NASDAQ: FBRX) - Stock Titan
Forte Biosciences stock (US34960P1012): Q1 2026 earnings report upcoming - AD HOC NEWS
Forte Biosciences Inc Stock (FBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):